Core Viewpoint - BeiGene has demonstrated strong execution in Q4 2025, achieving significant product revenue growth and solid cash flow, with its lead product, Brukinsa (Zebutinib), becoming the top BTK inhibitor globally [1][4][17]. Financial Performance - Q4 2025 product revenue reached $1.5 billion, a 33% year-over-year increase, with Brukinsa global revenue of $1.1 billion, up 38% [3][17]. - For the full year 2025, Brukinsa generated $3.9 billion in global revenue, reflecting a 49% increase [3][17]. - Gross margin improved to 87%, with operating profit of $447 million and GAAP net profit of $287 million for Q4 2025 [3][19]. - The company expects total revenue for 2026 to be between $6.2 billion and $6.4 billion, with GAAP operating expenses projected at $4.7 billion to $4.9 billion [3][21]. Product Development and Pipeline - In 2025, BeiGene made significant progress in R&D, with the approval of ZS in China for relapsed/refractory MCL and CLL, and ongoing regulatory reviews in the US and EU [2][8]. - The company is advancing multiple clinical trials, including three Phase 3 trials for BTK degraders and a combination therapy for HER2-positive gastric cancer [2][8][14]. - BeiGene aims to establish Brukinsa as a foundational treatment in CLL, with plans to expand its use in fixed-duration treatment regimens [10][11]. Market Position and Strategy - Brukinsa has established itself as the leading BTK inhibitor, with a market share of approximately 50% in the CLL treatment space [7][27]. - The company is targeting three ambitious goals for CLL innovation, focusing on improving patient outcomes and treatment options [6][10]. - BeiGene is also expanding its pipeline beyond CLL, with ongoing research in various hematologic malignancies and solid tumors [11][12][13]. Future Catalysts - Key upcoming milestones include the initiation of a global Phase 3 study comparing ZS with another oral fixed-duration treatment in newly diagnosed CLL patients [16][21]. - The company plans to submit a marketing application for ZS in combination with chemotherapy for HER2-positive gastric cancer in mid-2026 [16][21]. - BeiGene is also set to report on several concept validation studies in immunology throughout 2026 [16].

Core Insights - The company achieved its first annual profit since its establishment in 2025, with total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, reversing a loss of 4.978 billion yuan from the previous year [1][2] Financial Performance - Total revenue reached 38.205 billion yuan, up 40.4% from 27.214 billion yuan in the previous year [2] - Product revenue was 37.770 billion yuan, reflecting a 39.9% increase from 26.994 billion yuan [2] - Operating profit was 2.562 billion yuan, while total profit was 2.558 billion yuan, both transitioning from losses in the previous year [2] - Basic earnings per share improved from -3.64 yuan to 1.00 yuan [2] - The weighted average return on equity was 5.19%, recovering from -20.20% [2] Product Performance - The core product, Baiyueze® (Zebutinib), generated global sales of 28.067 billion yuan, a 48.8% increase, accounting for 73.5% of total revenue [3][5] - Sales in the U.S. market reached 20.206 billion yuan, up 45.5%, while European sales were 4.265 billion yuan, increasing by 66.4% [5] - Other product segments, including Bai Ze An® and licensed products from Amgen, contributed significantly, with total product revenue reaching 37.770 billion yuan, making up 98.9% of total revenue [6] Cash Flow and Assets - The company reported a significant increase in operating cash flow, with free cash flow reaching 9.42 billion yuan [7] - Total assets grew to 57.423 billion yuan, a 34.1% increase from the beginning of the period, while equity attributable to shareholders rose to 30.601 billion yuan, up 26.6% [7] Research and Development - R&D expenses for 2025 were 21.46 billion yuan, a 10% increase, but the proportion of R&D spending relative to revenue decreased to 40.4% [3][8] - The company has invested over 56 billion yuan in R&D since its inception, with 14.14 billion yuan spent in 2024 alone [3] Capital Structure and Shareholder Changes - Hillhouse Capital, a cornerstone investor, has reduced its stake from 8.97% to 4.89% through two rounds of share sales in 2025, cashing out approximately 7.146 billion HKD [4] - Other shareholders, including Amgen and Baker Brothers Life Sciences, maintained their holdings, while new investors have entered the shareholder base [4]

Core Viewpoint - BeiGene reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.4% driven by product revenue growth and improved operational efficiency through cost management [1] Group 1: Financial Performance - The net profit attributable to the parent company reached 1.422 billion yuan during the reporting period [1] - Product revenue amounted to 37.77 billion yuan, showing a year-on-year increase of 39.9% [1] Group 2: Product Sales - The global sales of the product Brukinsa® (Zebutinib) reached 28.067 billion yuan, with a year-on-year growth of 48.8% [1] - In the U.S. market, Brukinsa® sales were 20.206 billion yuan, reflecting a year-on-year increase of 45.5% [1] - In Europe, Brukinsa® sales reached 4.265 billion yuan, growing by 66.4% year-on-year [1] - In China, Brukinsa® sales were 2.472 billion yuan, with a year-on-year growth of 33.1% [1] - Another core product, Tislelizumab (百泽安®), achieved global sales of 5.297 billion yuan, marking an 18.6% increase year-on-year [1] Group 3: Future Prospects - BeiGene plans to submit a new indication application for Tislelizumab combined with Zanidatamab (Zanidatamab) for first-line treatment of HER2-positive gastric adenocarcinoma in adults in the U.S. and China in the first half of 2026 [1] - The company anticipates a regulatory decision in Japan for the same indication in the second half of 2026 [1]

Core Viewpoint - BeiGene has reported a significant increase in revenue and net profit for the fiscal year 2025, indicating a successful transition from a loss-making entity to a profitable one, driven by strong product sales and effective cost management [1][3]. Financial Performance - Total revenue for 2025 reached RMB 38.205 billion, a year-on-year increase of 40.4% [1]. - Net profit attributable to the parent company was RMB 1.422 billion [1]. - Product revenue amounted to RMB 37.770 billion, reflecting a growth of 39.9% [1]. Product Performance - The sales of the leading product, Brukinsa® (Zebutinib), reached RMB 28.067 billion, marking a 48.8% increase [1]. - In the U.S., Brukinsa® sales were RMB 20.206 billion, up 45.5% [1]. - In Europe, sales were RMB 4.265 billion, a growth of 66.4% [1]. - In China, sales reached RMB 2.472 billion, increasing by 33.1% [1]. Market Expansion and Clinical Trials - Brukinsa® is now approved in over 75 markets globally, establishing itself as the most widely approved BTK inhibitor [2]. - Upcoming clinical trials include a mid-term analysis of the MANGROVE trial for Brukinsa® in combination with Rituximab for adult patients with mantle cell lymphoma [2]. - The sales of another key product, Tislelizumab (百泽安®), reached RMB 5.297 billion, an 18.6% increase [2]. Future Projections - Revenue for 2026 is projected to be between RMB 43.6 billion and RMB 45 billion, with a gross margin expected to remain high at around 80% [4]. - Research and development expenses are anticipated to be between RMB 33.3 billion and RMB 34.8 billion [4]. Pipeline and Innovation - The company is advancing several late-stage products in the hematologic oncology field, including the BCL2 inhibitor, which has received approval for its first global marketing application in China [4]. - The introduction of BTK inhibitors and IRAK4 degraders into autoimmune diseases represents a strategic expansion into non-oncology markets [5]. Market Position and Valuation - Despite achieving profitability, the company's market valuation remains high, with a significant price-to-earnings ratio, indicating that the market views it as a growth stock rather than a value stock [5].

Market Dynamics - China's AI model API usage has surpassed that of the US for the first time, with a total of 41.2 trillion tokens compared to the US's 29.4 trillion tokens during the week of February 9-15. This represents a significant increase of 127% in the following week, reaching 51.6 trillion tokens [1] - Four out of the top five AI models globally are from Chinese companies, contributing 85.7% of the total usage on the platform [1] - The majority of users on the platform are overseas developers, with 47.17% from the US and only 6.01% from China, indicating the global appeal of Chinese AI models [1] Company Updates - Nvidia experienced its largest single-day drop in 10 months, with a market value loss of $245.2 billion (approximately 1677.5 billion RMB), as its stock fell over 5% [2] - Baidu reported fourth-quarter revenue of 32.74 billion RMB, a 5% increase quarter-over-quarter, aligning with market expectations. The company also noted a non-GAAP net profit of 3.9 billion RMB for the same period [4] - BeiGene is projected to achieve a net profit of 1.422 billion RMB in 2025, marking a turnaround from losses in previous years, with total revenue expected to reach 38.205 billion RMB, a 40.4% increase year-over-year [6] - Chip manufacturer ASML announced that its next-generation EUV lithography machines are ready for mass production, with a unit price of approximately $400 million [5] - NAND flash memory prices are rising due to ongoing supply shortages, prompting major manufacturers like Phison to require prepayments from customers to secure stable supply [6] - Tsinghua Unigroup reported a net loss of 6.994 billion RMB for 2025, with total revenue of 67.279 billion RMB, a 16.2% decrease from the previous year [9]

Group 1: Company Performance - BeiGene reported a total revenue of 38.205 billion yuan for 2025, a year-on-year increase of 40.4%, with a net profit of 1.422 billion yuan, marking a return to profitability [1] - Chipone Technology achieved a revenue of 3.152 billion yuan in 2025, up 35.77% year-on-year, with a narrowed net loss of 528 million yuan compared to a loss of 601 million yuan in the previous year [2] - Purans reported a total revenue of 2.32 billion yuan for 2025, a year-on-year increase of 28.62%, with a net profit of 208 million yuan, down 28.79% year-on-year [4] - Zhenray Technology saw a net profit increase of 582.01% in 2025 [11] - Jinlongyu reported a net profit increase of 26.01% in 2025 [12] Group 2: Product and Market Insights - BeiGene's product revenue reached 37.77 billion yuan, driven by sales growth of its products including Brukinsa and Tislelizumab [1] - Chipone Technology's mass production business revenue is expected to grow by 73.98%, with AI-related orders accounting for over 73% of new orders [2] - Purans' revenue growth was attributed to favorable changes in the storage chip market and increased demand for its products [4] Group 3: Strategic Developments - Huadian Electric is planning to sell its subsidiary Huangshi Supply Chain Management Co., Ltd. to focus on its core business [3] - Chipone Technology signed new orders worth 5.96 billion yuan, a 103.41% increase year-on-year [2] - Feilihua is in the testing phase for its ultra-thin quartz electronic cloth, which is expected to contribute about 5% to its overall revenue in 2025 [5]

Group 1 - The core viewpoint of the article highlights that BeiGene (688235.SH) reported a total revenue of 38.205 billion yuan for the fiscal year 2025, marking a year-on-year increase of 40.4%, and a net profit attributable to the parent company of 1.422 billion yuan, reversing from a loss to profit [1][2] - The company's product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year, driven primarily by the sales growth of Brukinsa® (Zebutinib), licensed products from Amgen, and Tislelizumab [1][2] - Global sales of Brukinsa® totaled 28.067 billion yuan, reflecting a year-on-year growth of 48.8%, solidifying its position as a global leader in the BTK inhibitor market [2] Group 2 - The company anticipates that its revenue for 2026 will range between 43.6 billion yuan and 45 billion yuan, with a gross margin expected to remain high at around 80% [2] - Adjusted operating costs for 2026 are projected to be between 9.8 billion yuan and 10.5 billion yuan [2] - As of the market close on the day of the report, BeiGene's stock price fell by 5.65%, with a market capitalization of 405.88 billion yuan [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司2025年度業績快 報公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2026年2月26日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執 行董事王曉東博士，以及獨立非執行董事 Olivier Brandicourt 博士、 Margaret Han Dugan博士、Michael Goller先生、Anthony C. Hooper先生、 Ranjeev Krishana先生、Alessandro Riva博士、Corazon (Cor ...

Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, while total assets increased by 34.1% to 57.423 billion yuan, and equity attributable to the parent company rose by 26.6% to 30.601 billion yuan [1] Product Performance - The global sales of Baiyueze® reached 28.067 billion yuan, marking a 48.8% year-on-year growth, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, a 45.5% increase, while European sales were 4.265 billion yuan, up 66.4%, and sales in China totaled 2.472 billion yuan, increasing by 33.1% [2] - Bai Ze An® achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth, and sales from Amgen's licensed products reached 3.471 billion yuan, up 33.6% [2] Clinical Development and Regulatory Approvals - Baiyueze® is the most widely approved BTK inhibitor globally, with over 45 clinical trials conducted across more than 30 countries, enrolling over 7,900 patients [3] - The drug has received regulatory approvals in over 75 markets and demonstrated significant benefits in progression-free survival (PFS) in clinical trials, reinforcing its status as a preferred BTK inhibitor [3] - Bai Ze An® has shown potential across various tumor types, with clinical trials involving over 15,800 participants in more than 33 countries, and has been approved in over 50 markets [4] - The company plans to submit new indications for Bai Ze An® in the U.S. and China in the first half of 2026, with expectations for regulatory decisions in Japan by the second half of 2026 [4]

Core Insights - The company reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.40% [1] - The net profit attributable to shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the same period last year [1] - The basic earnings per share stood at 1 yuan [1] Revenue Breakdown - Product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year [1] - The growth in product revenue was primarily driven by sales of Baiyueze® (Zebutinib), licensed products from Amgen, and Baizean® (Tislelizumab) [1]